Cargando…

A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other Genotype

Molecular classification of lung cancer correlates well with histomorphological features. However, specific histomorphological features that differentiate anaplastic lymphoma kinase (ALK)-rearranged tumors from ALK-negative tumors have not been fully evaluated. Eighty ALK-rearranged and 213 ALK-nega...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyojin, Jang, Se Jin, Chung, Doo Hyun, Yoo, Seol Bong, Sun, Pingli, Jin, Yan, Nam, Kyung Han, Paik, Jin-Ho, Chung, Jin-Haeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806726/ https://www.ncbi.nlm.nih.gov/pubmed/24194854 http://dx.doi.org/10.1371/journal.pone.0076999

Ejemplares similares

Alteration of the E-Cadherin/β-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma
por: Kim, Hyojin, et al.
Publicado: (2013)

Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group
por: Kim, Hyojin, et al.
Publicado: (2014)

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
por: Kim, Hyojin, et al.
Publicado: (2016)

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients
por: Kim, Sheehyun, et al.
Publicado: (2023)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Immunohistochemical demonstration of alteration of β-catenin during tumor metastasis by different mechanisms according to histology in lung cancer
por: XU, XIANHUA, et al.
Publicado: (2015)

Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment
por: Lee, Hyun Ju, et al.
Publicado: (2013)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
por: Choi, Se Hoon, et al.
Publicado: (2017)

The EML4-ALK oncogene: targeting an essential growth driver in human cancer
por: MANO, Hiroyuki
Publicado: (2015)

PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
por: Kim, Hyojin, et al.
Publicado: (2019)

Correction of acknowledgments: PD-L1 testing in non-small cell lung cancer: past, present, and future
por: Kim, Hyojin, et al.
Publicado: (2020)

Biomarker testing of cytology specimens in personalized medicine for lung cancer patients
por: Kim, Hyojin, et al.
Publicado: (2022)

Frequently rearranged in advanced T-cell lymphomas-1 demonstrates oncogenic properties in prostate cancer
por: Zhang, Wei, et al.
Publicado: (2016)

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
por: Schoepflin, Zachary R., et al.
Publicado: (2023)

Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma
por: Ahn, Hyein, et al.
Publicado: (2017)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2020)

Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report
por: Huang, Jie, et al.
Publicado: (2022)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

Estrogen receptor α as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma
por: Kwon, Soohyeon, et al.
Publicado: (2020)

ALK rearrangement in lung adenocarcinoma with concurrent cervix and breast metastases: A case report
por: Chuang, Xin, et al.
Publicado: (2018)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement
por: Kim, Hee Joung, et al.
Publicado: (2015)

Heterotopic Pancreas in Omphalomesenteric Duct Remnant Results in Persistent Umbilical Discharge
por: Park, Eunhyang, et al.
Publicado: (2014)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
por: Leung, Jackson Ka Chun, et al.
Publicado: (2023)

Development of a novel ALK rearrangement screening test for non–small cell lung cancers
por: Chen, Yi-Lin, et al.
Publicado: (2021)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q0saaomoo5qi0pr5hdqt81dnt7